1. Volume 114, Issue 6, Pages 1133-1142 (June 1998)
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease 
Bruce R. Yacyshyn, Mary Beth Bowen-Yacyshyn, Lawrence Jewell, Joseph A. Tami, C.Frank Bennett, Daniel L. Kisner, William R. Shanahan 
Gastroenterology 
Volume 114, Issue 6, Pages (June 1998)
DOI: /S (98)
Copyright © 1998 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Mean CDAI scores over time for the combined ISIS 2302 (•) and placebo (▴) groups. Standard error bars are displayed. None of the differences in change from baseline reached statistical significance (P = 0.25 and 0.38 on days 33 and 40, respectively, in favor of ISIS 2302; P = 0.21 in favor of placebo on day 60).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Mean EIS scores over time for the combined ISIS 2302 (•) and placebo (▴) groups. Standard error bars are displayed. None of the differences in change from baseline reached statistical significance (P = 0.26 at all time points).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Mean IBDQ scores over time for the combined ISIS 2302 (•) and placebo (▴) groups. Standard error bars are displayed. Improvement from baseline was significantly greater in antisense-treated patients on day 40 (P = 0.022) but was not significant on any other day (day 26, P = 0.102; day 60, P = 0.082; all other days, P > 0.8).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

5. Fig. 4
Mean corticosteroid dose over time for the combined ISIS 2302 (•) and placebo (▴) groups. Standard deviation bars are displayed. The difference in corticosteroid dosage over time between the two treatment groups is statistically significant (P = , repeated-measures ANOVA).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

6. Fig. 5
Mean percent change in CD3+ peripheral blood lymphocytes expressing β7. •, ISIS 2302; ▴, placebo. Standard error bars are displayed. Differences reached statistical significance only on day 26 (P = 0.007), but approached significance on day 56 (P = 0.053).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

7. Fig. 6
Mean percent change in CD3+ peripheral blood lymphocytes expressing αd. •, ISIS 2302; ▴, placebo. Standard error bars are displayed. Only the patients receiving 2 mg/kg (9 drug-treated, 3 placebo treated) were evaluated because of late availability of the reagent. Only the difference on day 13 was statistically significant (P = 0.025).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

8. Fig. 7
ICAM-1 expression by immunohistochemical staining in representative (A) day 1 and (B) day 26 mucosal biopsy specimens, taken from the same area of the gastroduodenum of a patient treated with 2 mg/kg of ISIS 2302.
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions